```html

Kawasaki‑like Syndrome (Multisystem Inflammatory Syndrome in Children – MIS‑C)

What is Kawasaki-like syndrome (MIS‑C)?

Multisystem Inflammatory Syndrome in Children (MIS‑C), sometimes called Kawasaki‑like syndrome, is a rare but serious condition that appears weeks after a child or adolescent has been infected with SARS‑CoV‑2, the virus that causes COVID‑19. The illness shares many features with classic Kawasaki disease — fever, rash, red eyes, and inflammation of blood vessels — but it typically involves more widespread organ involvement, including the heart, gastrointestinal tract, and nervous system.

MIS‑C is considered an abnormal immune response: the body’s immune system becomes hyper‑activated, releasing large amounts of inflammatory chemicals (cytokines) that can damage multiple organ systems. Although most children recover with prompt treatment, the condition can be life‑threatening if not recognized early.

Sources: CDC, WHO, American Academy of Pediatrics (AAP)

Common Causes

While the exact trigger for MIS‑C is still being studied, the syndrome is most often linked to the following conditions or exposures:

• Recent SARS‑CoV‑2 infection – most cases occur 2–6 weeks after COVID‑19 or after a positive antibody test.
• Asymptomatic COVID‑19 exposure – children can develop MIS‑C even if they never had noticeable symptoms.
• Other viral infections – rare reports link influenza, adenovirus, or enterovirus infections to Kawasaki‑like inflammation.
• Genetic predisposition – certain HLA types and ethnic backgrounds (e.g., children of Asian or Black ancestry) appear at higher risk.
• Immune dysregulation disorders – pre‑existing autoimmune diseases can amplify the inflammatory response.
• Severe bacterial infections – in rare cases, a bacterial sepsis can mimic or trigger a Kawasaki‑like picture.
• Vaccination (extremely rare) – isolated case reports have described MIS‑C‑like illness after COVID‑19 vaccination, but causality is not established.
• Toxin exposure – environmental toxins have been hypothesized but lack solid evidence.
• Other inflammatory conditions – such as systemic juvenile idiopathic arthritis, which can overlap clinically.
• Unknown trigger – in a minority of children no clear antecedent is identified.

Associated Symptoms

MIS‑C presents with a constellation of signs that affect at least two organ systems. The most common symptoms include:

• Persistent fever (≥38.0 °C / 100.4 °F) lasting ≥3 days.
• Rash – often polymorphous, may be maculopapular or resembling “strawberry tongue.”
• Conjunctival injection – red eyes without discharge.
• Oral changes – cracked, red lips; strawberry tongue.
• Swollen hands and feet – erythema and edema.
• Gastrointestinal symptoms – abdominal pain, vomiting, diarrhea.
• Cardiac involvement – myocarditis, pericarditis, coronary artery dilation/aneurysm, reduced ejection fraction.
• Neurologic signs – headache, irritability, confusion, or seizures.
• Respiratory distress – shortness of breath, cough, or hypoxemia (often due to cardiac dysfunction).
• Elevated inflammatory markers – high C‑reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, D‑dimer, and troponin.

When to See a Doctor

Because MIS‑C can deteriorate rapidly, parents and caregivers should seek medical attention promptly if a child has:

• Fever lasting more than 24–48 hours without an obvious cause.
• Any combination of rash, red eyes, swollen lips/tongue, or swollen hands/feet.
• Severe abdominal pain, persistent vomiting, or diarrhea.
• Rapid breathing, chest pain, or a feeling of “tightness” in the chest.
• Signs of dehydration (dry mouth, very little urine, dizziness).
• New‑onset fatigue, confusion, or irritability that is out of proportion to the child’s usual behavior.
• Any known recent COVID‑19 infection or close contact with a confirmed case within the past 2–6 weeks.

Diagnosis

Diagnosing MIS‑C requires a combination of clinical assessment, laboratory testing, and imaging. The CDC and WHO provide case definitions that include:

Step‑by‑step evaluation

1. Clinical criteria
   • Fever ≥38 °C for ≥24 hours.
   • At least two of the following: rash, conjunctivitis, oral mucosal changes, peripheral extremity changes, lymphadenopathy.
   • Evidence of organ involvement (cardiac, gastrointestinal, renal, hematologic, neurologic, or respiratory).
2. Laboratory evidence of inflammation
   • Elevated CRP, ESR, procalcitonin, ferritin, D‑dimer, fibrinogen, IL‑6.
   • Elevated cardiac markers (troponin, BNP/NT‑proBNP).
   • Neutrophilia, lymphopenia, thrombocytopenia.
3. Evidence of recent SARS‑CoV‑2 exposure
   • Positive PCR or antigen test, or positive serology (IgG antibodies).
   • Documented exposure to a confirmed case within the previous 2–6 weeks.
4. Exclusion of alternative diagnoses
   • Rule out bacterial sepsis, toxic shock syndrome, viral myocarditis, and classic Kawasaki disease.
5. Imaging
   • Echocardiogram – assesses ventricular function, pericardial effusion, and coronary artery size.
   • Chest X‑ray or CT – evaluates pulmonary involvement.
   • Abdominal ultrasound/CT – may show ascites or bowel inflammation.

Treatment Options

Treatment aims to halt the hyper‑inflammatory response, support organ function, and prevent long‑term cardiac damage.

Hospital‑based medical therapy

• Intravenous immunoglobulin (IVIG) – 2 g/kg given over 8–12 hours; first‑line therapy similar to Kawasaki disease.
• Corticosteroids – methylprednisolone or prednisone; often added if fever persists after IVIG.
• Aspirin – high‑dose (30–50 mg/kg/day) during the acute phase, then low‑dose antiplatelet (3–5 mg/kg/day) after fever resolves.
• Biologic agents – anti‑IL‑6 (tocilizumab), anti‑IL‑1 (anakinra), or infliximab for refractory cases.
• Anticoagulation – low‑molecular‑weight heparin or enoxaparin if D‑dimer is markedly elevated or if coronary aneurysms develop.
• Supportive care
  • Oxygen therapy or mechanical ventilation for respiratory failure.
  • Fluid resuscitation and vasopressors for shock.
  • Inotropic agents (e.g., milrinone) for myocardial dysfunction.

Home care after discharge

• Continue low‑dose aspirin as instructed.
• Monitor temperature twice daily; seek help if fever returns.
• Gradual return to activity; avoid intense sports for at least 4–6 weeks or until cardiac clearance.
• Follow up with pediatric cardiology for repeat echocardiograms (usually at 1–2 weeks, 6 weeks, and 6 months).
• Maintain a balanced diet and hydration; mild fatigue is common during recovery.

Prevention Tips

Because MIS‑C is closely linked to COVID‑19, the most effective preventive measures target the virus itself.

• Vaccination – COVID‑19 vaccines approved for children 6 months and older dramatically lower the risk of severe infection and subsequent MIS‑C.
• Public‑health measures – mask‑wear in crowded indoor settings, regular hand‑washing, and adequate ventilation.
• Prompt testing – isolate and test children with COVID‑19 symptoms or known exposure.
• Early treatment of COVID‑19 – antiviral therapy (e.g., Paxlovid for eligible children) may reduce viral load and inflammatory sequelae.
• Routine health check‑ups – keep pediatric appointments up to date for growth monitoring and early detection of abnormal signs.
• Educate caregivers – awareness of MIS‑C symptoms ensures timely medical evaluation.

Emergency Warning Signs

Early recognition and treatment of Kawasaki‑like syndrome (MIS‑C) save lives and reduce the risk of permanent heart damage. If you suspect your child may be developing this condition, do not wait—seek medical care right away.

```